Its the report that keeps on giving. Here are two more...

Its the report that keeps on giving. Here are two more observations;

Firstly, we have a concise explanation for why ATL1102 stalled in MS following an out licencing agreement. The details make for interesting reading and provide important context. Secondly, the strong possibility exists that ATL1102 may be just entering its therapeutic range at the dosage level of 25 mg per week.

A paradigm shift has clearly occurred in RNA therapeutics and gene therapy giving rise to the dawn of precision medicine. Its somewhat interesting to note that RNA therapeutics may be ahead of the curve compared to gene therapy. The development of ATL1102 as a therapeutic was stalled, however, its time has now arrived due to the nexus of its mode of action and the growing popularity of RNA drugs in providing real answers to difficult-to-treat disease indications. At some future point, we may look back in time and find that CD49d is universally accepted as a critical target in inflammation. Arguably, that time has arrived. Finally, if 25mg per week turns out to be the dosage where ATL1102 is just entering its therapeutic range, then what is regarded as important efficacy signals could become a life changing medical breakthrough giving rise to hope not only in Duchenne's but across the inflammation spectrum.